FORECAST-2: World-First Trial Uses Tumor Organoids to Personalize Bowel Cancer Treatment
• A groundbreaking clinical trial launched in Melbourne aims to revolutionize bowel cancer treatment by using patient-derived tumor organoids to predict drug responses before treatment begins.
• The FORECAST-2 trial builds on landmark research showing organoids can predict ineffective treatments with 90% accuracy and effective treatments with 83% accuracy, potentially eliminating months of ineffective therapy.
• Bowel cancer, Australia's second deadliest cancer with over 5,000 annual deaths, could see improved survival rates through this personalized medicine approach that replaces current trial-and-error treatment selection.
© Copyright 2025. All Rights Reserved by MedPath